Introduction Malignant pleural mesothelioma is an infrequent and aggressive type of cancer
that is difficult to treat, and standard therapies have shown limited effectiveness. There have …

Background Malignant pleural mesothelioma is a highly aggressive cancer with poor
prognosis and few treatment options following progression on platinum-containing …

The only registered systemic treatment for malignant pleural mesothelioma (MPM) is
platinum based chemotherapy combined with pemetrexed, with or without bevacizumab …

Malignant pleural mesothelioma (MPM) represents the uncommon cancer originating from
pleural mesothelial cells, which is associated with dismal prognostic outcome. According to …

Introduction There is no approved second-line treatment for malignant pleural mesothelioma
(MPM). On the basis of promising early results, pembrolizumab was used off-label in …

Simple Summary Advances in malignant pleural mesothelioma research have led to the
approval of first-line immunotherapies and the development of numerous trials of new first …

Background: The programmed death receptor 1 (PD-1) pathway is implicated in evasion of
the antitumor immune response. Pembrolizumab is a potent, highly selective humanized …

The management of pleural mesothelioma has changed with the demonstration that first-line
checkpoint blockade therapy improves survival. This review covers issues of relevance to …

Background Malignant pleural mesothelioma (MPM) is a highly aggressive cancer with poor
prognosis and limited treatment options after progression on platinum-containing …

Malignant pleural mesothelioma is a rare and aggressive malignancy arising from
mesothelial cells that line the serous membranes of the body. Cytotoxic chemotherapy has …